Half-year report · Q2

Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥6.3bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥13.1bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥6.4bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income−¥111m2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥89m2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income−¥157m2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥108m2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥95m2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax−¥195m2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥94m2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)−¥182m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥4m2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥48m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income−¥185m2024-04-01 → 2024-09-30Cons.Profit loss
Net income¥42m2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥10.6bnat 2024-09-30Cons.Assets
Total assets¥9.8bnat 2024-03-31Cons.Assets
Total assets¥10.5bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥4.8bnat 2024-09-30Cons.Liabilities
Total liabilities¥3.8bnat 2024-03-31Cons.Liabilities
Net assets / equity¥5.8bnat 2024-09-30Cons.Net assets
Net assets / equity¥6.0bnat 2024-03-31Cons.Net assets
Net assets / equity¥6.1bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥2.3bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥2.5bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥2.2bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥2.5bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥2.9bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥3.5bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow−¥421m2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥392m2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥366m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥175m2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥281m2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥129m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥379m2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥343m2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥47m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-10.972024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥0.242023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥2.872023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio53.5%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio60.1%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio57.4%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 31
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥3m
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥3m
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥114m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥806m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥803m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥3m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2024-04-01 → 2024-09-30−¥189m
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥5.5bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥5.5bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥45,000
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥192m
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2024-09-30¥6.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2024-09-30¥6.3bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2024-09-30¥3m
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2024-09-30¥3m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥3m
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-09-30¥450,000
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥4m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥108m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥981m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥978m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥27m
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥5.4bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥5.4bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥628,000
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥223m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥6.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥6.4bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥4m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥196m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 501
ItemContextValueUnit
Income taxes paid ope cfPrior1YTDDuration-55566000JPY
Income taxes paid ope cfCurrentYTDDuration-57158000JPY
Income taxes refund ope cfPrior1YTDDuration234250000JPY
Income taxes refund ope cfCurrentYTDDuration99053000JPY
Net cash provided by used in operating activitiesPrior1YTDDuration-365546000JPY
Net cash provided by used in operating activitiesCurrentYTDDuration-421145000JPY
Payments into time deposits inv cfPrior1YTDDuration-1500000JPY
Payments into time deposits inv cfCurrentYTDDuration-2040000JPY
Purchase of property plant and equipment inv cfPrior1YTDDuration-109795000JPY
Purchase of property plant and equipment inv cfCurrentYTDDuration-73968000JPY
Proceeds from sales of property plant and equipment inv cfPrior1YTDDuration-JPY
Proceeds from sales of property plant and equipment inv cfCurrentYTDDuration74000JPY
Payments for investments in capital inv cfPrior1YTDDuration-8000000JPY
Payments for investments in capital inv cfCurrentYTDDuration-JPY
Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cfPrior1YTDDuration-JPY
Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cfCurrentYTDDuration-80382000JPY
Other net inv cfPrior1YTDDuration-9812000JPY
Other net inv cfCurrentYTDDuration-18350000JPY
Net cash provided by used in investment activitiesPrior1YTDDuration-129107000JPY
Net cash provided by used in investment activitiesCurrentYTDDuration-174666000JPY
Redemption of bonds fin cfPrior1YTDDuration-7000000JPY
Redemption of bonds fin cfCurrentYTDDuration-7000000JPY
Increase decrease in short term loans payable fin cfPrior1YTDDuration320000000JPY
Increase decrease in short term loans payable fin cfCurrentYTDDuration652000000JPY
Proceeds from long term loans payable fin cfPrior1YTDDuration-JPY
Proceeds from long term loans payable fin cfCurrentYTDDuration50000000JPY
Repayment of long term loans payable fin cfPrior1YTDDuration-260145000JPY
Repayment of long term loans payable fin cfCurrentYTDDuration-241051000JPY
Repayments of lease obligations fin cfPrior1YTDDuration-8636000JPY
Repayments of lease obligations fin cfCurrentYTDDuration-8583000JPY
Payments for long term accounts payable other fin cfPrior1YTDDuration-8067000JPY
Payments for long term accounts payable other fin cfCurrentYTDDuration-8067000JPY
Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cfPrior1YTDDuration-JPY
Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation fin cfCurrentYTDDuration-8813000JPY
Cash dividends paid fin cfPrior1YTDDuration-82924000JPY
Cash dividends paid fin cfCurrentYTDDuration-49647000JPY
Net cash provided by used in financing activitiesPrior1YTDDuration-46774000JPY
Net cash provided by used in financing activitiesCurrentYTDDuration378836000JPY
Effect of exchange rate change on cash and cash equivalentsPrior1YTDDuration2742000JPY
Effect of exchange rate change on cash and cash equivalentsCurrentYTDDuration-4150000JPY
Net increase decrease in cash and cash equivalentsPrior1YTDDuration-538686000JPY
Net increase decrease in cash and cash equivalentsCurrentYTDDuration-221126000JPY
Cash and cash equivalentsPrior2YearInstant3459447000JPY
Cash and cash equivalentsPrior1YearInstant2466101000JPY
Cash and cash equivalentsPrior1QuarterInstant2920760000JPY
Cash and cash equivalentsCurrentQuarterInstant2244975000JPY
Salaries and allowances sgaPrior1YTDDuration249505000JPY
Salaries and allowances sgaCurrentYTDDuration299265000JPY
Retirement benefit expenses sgaPrior1YTDDuration2523000JPY
Retirement benefit expenses sgaCurrentYTDDuration2171000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass